Vanguard Portfolio Management’s Immuneering IMRX Stock Holding History

Vanguard Portfolio Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	+359,085	New	+$1.82M	﹤0.01%	2781

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Vanguard Portfolio Management's IMRX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Immuneering (IMRX) in Q2 2026: 359,085 shares worth $1.79M. The stake represents ﹤0.01% of the portfolio and ranks #2781 among its holdings.

111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

Vanguard Portfolio Management held 359,085 shares of Immuneering worth $1.79M as of Q2 2026.
Immuneering was a new Vanguard Portfolio Management position in Q2 2026.
Immuneering made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2781 holding.
111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.